2025 Programme
Session times and titles are subject to change
The sponsors did not provide any input or control over the agenda, content
creation, or speaker selection, except for their sponsored sessions.
Vaccinations is a discipline in medicine where everything moves fast. This presentation will help delegates keep up with changes in vaccinations and immunisations.
Meningococcal B disease is a rare but serious illness caused by Neisseria meningitidis group B, often presenting as meningitis or septicemia. The bacteria commonly colonise the nasopharynx without causing illness, and individuals can carry them without symptoms. The 4CMenB vaccine was added to the routine infant schedule in September 2015, with changes from 1 July 2025 to optimise protection. The vaccine also offers some protection against Neisseria gonorrhoeae, the cause of gonorrhoea. A targeted vaccination programme for gay, bisexual, and other men who have sex with men (GBMSM) began via sexual health services on 1 August 2025.
This session will address some of the key issues which impact the delivery of travel health services in a primary care setting. It will consider some of the most frequently asked questions for travel vaccines and look briefly at a selection of new products on the market, available for travellers.
Under the surface of national childhood vaccination coverage, inequalities are widening—often hidden beneath the surface of aggregated statistics. In this session, Jon Mitchell, Clinical Lead for the Improving Immunisation Uptake Team at NHS SCW CHIS, and Molly Wescott, CHIS Project & Delivery Manager, explore how Primary Care can use their data to identify and address these disparities. Drawing on child health project, safeguarding, and implementation experience, they will share practical tips for improving accessibility, enhancing communication, and identifying at-risk children—such as those not registered with a GP—to support more equitable and inclusive immunisation delivery.
There is little doubt of the value of vaccinations and immunisation. Global travel has provided pathogens the opportunity to relocate rapidly and extensively. The impact of this can be devastating on individuals, families, communities and the wider global community. Vaccine Hesitancy is growing driven by a number of factors. This presentation will review the importance of travel vaccination and focus on Vaccine Hesitancy, how it can be understood and strategies for addressing this.
Since 2020, the development and distribution of vaccines have undergone transformative changes. The COVID-19 pandemic accelerated the adoption of mRNA technology and this innovation has broadened the horizon for vaccines targeting other diseases, such as cancer and malaria. Global vaccine production and distribution systems improved but disparities in access and uptake of vaccines remain an issue. Growing vaccine hesitancy and misinformation have become key challenges post COVID-19. Uptake also varies across the UK due to decreasing trust, infrastructure, and socioeconomic conditions. This session will look at what has redefined the landscape of immunization, highlighting both achievements and ongoing challenges.
Session focused on supporting primary care nurses involved in the provision of travel medicine. To include guidance on appropriate information resources, patient engagement and enabling traveller decision-making.
Vaccinations is a discipline in medicine where everything moves fast. This presentation will help delegates keep up with changes in vaccinations and immunisations.
This session will address some of the key issues which impact the delivery of travel health services in a primary care setting. It will consider some of the most frequently asked questions for travel vaccines and look briefly at a selection of new products on the market, available for travellers.
This promotional symposium is organised and funded by Pfizer Ltd, intended for UK healthcare professionals and will include reference to Pfizer medicines relevant to the agenda topics. Company products will be discussed.
Delivering Respiratory Syncytial Virus (RSV) Immunisation Programmes to Help Protect your Patients from RSV Disease and Practical Tips about Vaccination Conversations with Patients.
Wednesday 24th September 2025 at 11:45 -12:30
Ludgate room - In a private meeting room, 1 America Square, 17 Crosswall, London, EC3N 2LB
Speakers:
-Katie Byrne, Registered Nurse, Midwife and Lecturer
- Dr Catherine Heffernan, Director of Health Improvement, Consultant in Public Health & Visiting Senior Lecturer at King’s College London
During the symposium the speakers will discuss:
• The burden of RSV disease
• Clinical trial data and real-world evidence from RSV immunisation implementation programmes.
• Practical tips about vaccination conversations with patients
• Questions & Answers with the audience
PP-A1G-GBR-0358 August 2025
There is little doubt of the value of vaccinations and immunisation. Global travel has provided pathogens the opportunity to relocate rapidly and extensively. The impact of this can be devastating on individuals, families, communities and the wider global community. Vaccine Hesitancy is growing driven by a number of factors. This presentation will review the importance of travel vaccination and focus on Vaccine Hesitancy, how it can be understood and strategies for addressing this.
Since 2020, the development and distribution of vaccines have undergone transformative changes. The COVID-19 pandemic accelerated the adoption of mRNA technology and this innovation has broadened the horizon for vaccines targeting other diseases, such as cancer and malaria. Global vaccine production and distribution systems improved but disparities in access and uptake of vaccines remain an issue. Growing vaccine hesitancy and misinformation have become key challenges post COVID-19. Uptake also varies across the UK due to decreasing trust, infrastructure, and socioeconomic conditions. This session will look at what has redefined the landscape of immunization, highlighting both achievements and ongoing challenges.
This session will consider the role of vaccination in pregnancy and the various vaccine programmes recommended for pregnant women. In the UK pregnant women are routinely recommended to receive vaccines against influenza, Pertussis, Respiratory Syncytial virus (RSV). The session will discuss these vaccine programmes and the rationale for protecting the pregnant women, the unborn infant and newborn baby for the first few months of life.
Vaccinations is a discipline in medicine where everything moves fast. This presentation will help delegates keep up with changes in vaccinations and immunisations.
Under the surface of national childhood vaccination coverage, inequalities are widening—often hidden beneath the surface of aggregated statistics. In this session, Jon Mitchell, Clinical Lead for the Improving Immunisation Uptake Team at NHS SCW CHIS, and Molly Wescott, CHIS Project & Delivery Manager, explore how Primary Care can use their data to identify and address these disparities. Drawing on child health project, safeguarding, and implementation experience, they will share practical tips for improving accessibility, enhancing communication, and identifying at-risk children—such as those not registered with a GP—to support more equitable and inclusive immunisation delivery.
There is little doubt of the value of vaccinations and immunisation. Global travel has provided pathogens the opportunity to relocate rapidly and extensively. The impact of this can be devastating on individuals, families, communities and the wider global community. Vaccine Hesitancy is growing driven by a number of factors. This presentation will review the importance of travel vaccination and focus on Vaccine Hesitancy, how it can be understood and strategies for addressing this.
Meningococcal B disease is a rare but serious illness caused by Neisseria meningitidis group B, often presenting as meningitis or septicemia. The bacteria commonly colonise the nasopharynx without causing illness, and individuals can carry them without symptoms. The 4CMenB vaccine was added to the routine infant schedule in September 2015, with changes from 1 July 2025 to optimise protection. The vaccine also offers some protection against Neisseria gonorrhoeae, the cause of gonorrhoea. A targeted vaccination programme for gay, bisexual, and other men who have sex with men (GBMSM) began via sexual health services on 1 August 2025.
This session will address some of the key issues which impact the delivery of travel health services in a primary care setting. It will consider some of the most frequently asked questions for travel vaccines and look briefly at a selection of new products on the market, available for travellers.
Since 2020, the development and distribution of vaccines have undergone transformative changes. The COVID-19 pandemic accelerated the adoption of mRNA technology and this innovation has broadened the horizon for vaccines targeting other diseases, such as cancer and malaria. Global vaccine production and distribution systems improved but disparities in access and uptake of vaccines remain an issue. Growing vaccine hesitancy and misinformation have become key challenges post COVID-19. Uptake also varies across the UK due to decreasing trust, infrastructure, and socioeconomic conditions. This session will look at what has redefined the landscape of immunization, highlighting both achievements and ongoing challenges.
This session will consider the role of vaccination in pregnancy and the various vaccine programmes recommended for pregnant women. In the UK pregnant women are routinely recommended to receive vaccines against influenza, Pertussis, Respiratory Syncytial virus (RSV). The session will discuss these vaccine programmes and the rationale for protecting the pregnant women, the unborn infant and newborn baby for the first few months of life.